Immuron (ASX: IMC) has entered into a research agreement with the primary paediatric teaching hospital of Harvard Medical School, to test the effect of the company’s colostrum product in people undergoing radiation therapy.
The partnership with the Dana-Farber Cancer Institute and Children’s Hospital Boston will test how the colostrum product can help reduce the side effects of cancer treatments, and extend to how it may treat newborn lung inflammation.
Early data generated from animal studies has been encouraging to date and has provided the impetus for ongoing research.
Under the agreement, Immuron will retain rights to any data generated relating to its technology.
Immuron is developing oral immunotherapy treatments using dairy derived antibody products for use in humans.
The company’s proprietary dairy derived polyclonal antibody platform produces antibodies potentially suited to treat a wide range of diseases including infectious disease (bacterial and viral), cancers and chronic inflammatory diseases.
These antibodies are designed for delivery to the gastro-intestinal tract, the upper respiratory tract and/or topically, as required.
Importantly, the production of dairy colostrum- derived polyclonal antibodies is cost efficient, especially when compared to monoclonal antibodies.